整体低甲基化是弥漫大B细胞淋巴瘤的独立预后因素
研究在67例肿瘤活检和74例血浆cfDNA中检测LINE1甲基化以评估整体甲基化水平。整体低甲基化与肿瘤活检(P=.001)和cfDNA(P=.009)的总生存期差相关,在多变量分析中是最强风险因素,活检HR为10.65(CI:2.03-55.81,P=.005),cfDNA HR为11.87(CI:2.80-50.20,P=.001),优于传统临床风险因素。整体低甲基化与DAPK1启动子高甲基化等其他表观遗传异常共存,有潜力作为预后生物标志物。
要点
- 整体低甲基化在部分弥漫大B细胞淋巴瘤病例中可检测到。
- 肿瘤活检和血浆cfDNA中整体低甲基化均与总生存期差相关。
- 整体低甲基化是多变量分析中最强风险因素,优于传统临床风险因素。
核心结论
- 整体低甲基化在肿瘤活检DNA和血浆cfDNA中均与弥漫大B细胞淋巴瘤总生存期差强相关,有潜力作为预后生物标志物。
研究设计与样本
- 研究纳入67例肿瘤活检DNA和74例患者血浆cfDNA样本,检测LINE1甲基化作为整体甲基化的替代指标。
主要发现
- 整体低甲基化与肿瘤活检总生存期差相关(P=.001),与cfDNA总生存期差相关(P=.009)。
- 多变量分析中,肿瘤活检整体低甲基化风险比HR为10.65(CI:2.03-55.81,P=.005),cfDNA整体低甲基化HR为11.87(CI:2.80-50.20,P=.001),均为最强风险因素。
- cfDNA层次聚类分析显示整体低甲基化与DAPK1启动子高甲基化等其他表观遗传异常共存。
临床怎么用
- 作者认为整体低甲基化有潜力作为弥漫大B细胞淋巴瘤的预后生物标志物用于临床。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Global hypomethylation has been linked to disease progression in several cancers, but has not been reported for Diffuse Large B Cell Lymphoma (DLBCL). This study aimed to assess global methylation in DLBCL and describe its prognostic value. Mean LINE1 methylation, a validated surrogate measure for global methylation, was measured in DNA from 67 tumor biopsies. Additionally, cell-free circulating DNA (cfDNA) in plasma samples from 74 patients was tested to assess the feasibility of global hypomethylation as a biomarker in liquid biopsies. LINE1 methylation was assessed using a commercially available kit, based on pyrosequencing of PCR amplified bisulfite-treated DNA. Global hypomethylation was detected in a subset of cases and was associated with poor overall survival in both tumor biopsies (P = .001) and cfDNA (P = .009). It was the strongest risk factor in multivariate analysis in both biopsies (HR: 10.65, CI: 2.03-55.81, P = .005) and cfDNA (HR: 11.87, CI: 2.80-50.20, P = .001), outperforming conventional clinical risk factors. Finally, hierarchical cluster analyses were performed for the cfDNA samples using previously published gene-specific methylation data. This analysis shows that global hypomethylation co-occurs with other epigenetic abnormalities, including DAPK1 promoter hypermethylation. In conclusion, we have shown that global hypomethylation is strongly associated with poor survival in DLBCL both when present in tumor biopsy DNA and when detected in plasma cfDNA, and has potential for clinical application as a prognostic biomarker.
引用
- Wedge E, Hansen JW, Garde C, et al. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma. Am J Hematol. 2017. PMID: 28378885. doi:10.1002/ajh.24751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。